NEW
YORK, June 20, 2023 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, is pleased to announce the
appointment of Dr. Vojislav "Vojo" Vukovic as its new Chief
Medical Officer (CMO).
Dr. Vukovic is an experienced drug development executive with a
distinguished career in cancer research and global clinical
development. His experience spans early to late-stage oncology
clinical projects and global medical affairs programs across
multiple anti-cancer modalities and tumor types. He has held the
position of Senior Vice President and Chief Medical Officer at
Aileron Therapeutics, Taiho Oncology Inc., and Synta
Pharmaceuticals Inc. overseeing various facets of clinical
development, medical affairs and corporate strategy.
Dr. Vukovic earned his MD from the University of Sarajevo, a MSc in Radiation Biology and a PhD
in Tumor Biology from the University of
Toronto. His work has been published in several high-impact
scientific journals, and he is a member of the American Association
for Cancer Research, the American Society of Clinical Oncology, the
American Society of Hematology, and the European Society for
Medical Oncology.
"We are excited to welcome Dr. Vukovic to the executive
leadership team," said Gerard
Michel, CEO of Delcath Systems. "Given Vojo's extensive
experience in oncology drug development and oncology medical
affairs he is well positioned to make a major contribution as
we prepare for the potential launch of Hepzato Kit and continue to
advance our interventional oncology platform."
Commenting on his appointment, Dr. Vukovic stated, "I am
thrilled to join Delcath Systems, a company that is at the
forefront of interventional oncology, developing innovative
treatment solutions for patients with primary and metastatic liver
cancers. I look forward to contributing to Delcath's mission to
enhance the standard of care for cancer patients."
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company's proprietary products, HEPZATO Kit (melphalan
hydrochloride for Injection/Hepatic Delivery System) and
CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous
hepatic perfusion (PHP) are designed to administer high-dose
chemotherapy to the liver while controlling systemic exposure and
associated side effects during a PHP procedure.
In the United States,
HEPZATO Kit is considered an investigational drug/device
combination product regulated as a drug by the United States
Food and Drug Administration (FDA). HEPZATO Kit is comprised
of the chemotherapeutic drug melphalan and Delcath's proprietary
Hepatic Delivery System (HDS). The HDS is used to surgically
isolate the liver while simultaneously filtrating hepatic venous
blood during melphalan infusion and washout. The use of the HDS
results in loco-regional delivery of a relatively high melphalan
dose, which can potentially induce a clinically meaningful tumor
response with minimal hepatotoxicity and reduce systemic exposure.
In the US, HEPZATO Kit was the subject of a February 14,
2023 new drug application resubmission to FDA for the
treatment of patients with unresectable hepatic-dominant metastatic
ocular melanoma (mOM), also known as metastatic uveal melanoma
(mUM). FDA has established an August 14,
2023 PDUFA date for the resubmission. In Europe, the device-only configuration of the
HDS is regulated as a Class III medical device and is approved for
sale under the trade name CHEMOSAT Hepatic Delivery System for
Melphalan, or CHEMOSAT, where it has been used in the conduct of
percutaneous hepatic perfusion procedures at major medical centers
to treat a wide range of cancers of the liver.
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-appoints-vojislav-vukovic-as-chief-medical-officer-301854928.html
SOURCE Delcath Systems, Inc.